---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-21-000031"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:32:15.635225+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37

## Summary
- Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).
- EYLEA U.S. net sales $1.47B (+12% YoY); Dupixent global net sales (Sanofi) $1.66B (+55% YoY).
- REGEN-COV contributed $804M (U.S. product sales $677M + Roche profit share); new U.S. government supply agreement for 1.4M doses.
- Pipeline: FDA expanded Dupixent to children 6-11 with asthma; positive Phase 3 data in CSU, EoE, prurigo nodularis; REGEN-COV BLA accepted for priority review.
- FY 2021 guidance updated: R&D lowered to $2.845-2.915B GAAP; SG&A narrowed to $1.76-1.83B; gross margin ~87.5% GAAP; capex reduced.

## SEC filing metadata
- accession: 0001804220-21-000031
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/0001804220-21-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422021000031/regn-20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-21-000031
- JSON: https://secwatch.observer/filing/0001804220-21-000031.json
- Plain text: https://secwatch.observer/filing/0001804220-21-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.